SETAP: epidemiology and prevention of stroke and transient
ischaemic attack in Czech patients with atrial fibrillation

J 2021

SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation

TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA et. al.

Basic information

Original name

SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation

Authors

TABORSKY, Milos (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic), Josef KAUTZNER (203 Czech Republic), Marek VICHA (203 Czech Republic), Renata AIGLOVA (203 Czech Republic), Vit GLOGER (203 Czech Republic), Marian FEDORCO (203 Czech Republic), Jaroslav DUBA (203 Czech Republic), Lukas DUSEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Monika BEZDEKOVA (203 Czech Republic) and Tomas SKALA (203 Czech Republic, guarantor)

Edition

EP Europace, Oxford, Oxford University Press, 2021, 1099-5129

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.486

RIV identification code

RIV/00216224:14110/21:00121729

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1093/europace/euaa261

UT WoS

000644500900009

Keywords in English

Atrial fibrillation; Stroke; Epidemiology; Prevalence; Prevention; Anticoagulation; European Union; Czech Republic

Abstract

V originále

Aims The aim of this study is to analyse the prevalence, epidemiology, and anticoagulation prevention of stroke or transient ischaemic attack (TIA) in Czech patients with atrial fibrillation (AF). Methods and results Retrospective observational analysis of diagnoses, procedures, and treatment reported to the Czech National Registry of Reimbursed Healthcare Services between 2015 and 2018. Prevalence of AF in 2018 was 4.3% of Czech population and the prevalence of stroke/TIA in AF patients was 22.3% with annual incidence of 181.62 cases per 100 000 inhabitants. In 2018, CHA(2)DS(2)-ASc score >= 4 was present in 98% AF patients in secondary and 59% in primary prevention, respectively, while the anticoagulation treatment was used by 71-81% of them. Between 2015 and 2018, the percentage of AF patients treated with warfarin monotherapy in primary prevention decreased from 35% to 31%, with acetylsalicylic acid (ASA) monotherapy from 18% to 16% and non-vitamin K antagonist oral anticoagulants (NOACs) monotherapy increased from 7% to 11%. In secondary prevention, the percentage of warfarin monotherapy treatment decreased from 35% to 32%, with ASA monotherapy from 20% to 18% and with NOACs monotherapy increased from 9% to 15%. Conclusion This study followed all Czech patients with AF. The unadjusted prevalence and incidence of AF was higher compared with other countries and 2019 European Society of Cardiology Statistics. The study identified several gaps in standard of reimbursed care. 20-30% of AF patients with other risk factors were without any prevention medication and the share of ASA monotherapy in treated patients was 16-18%.

Citovat

TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA, Vit GLOGER, Marian FEDORCO, Jaroslav DUBA, Lukas DUSEK, Jiří JARKOVSKÝ, Monika BEZDEKOVA and Tomas SKALA. SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation. EP Europace. Oxford: Oxford University Press, 2021, vol. 23, No 4, p. 539-547. ISSN 1099-5129. Available from: https://dx.doi.org/10.1093/europace/euaa261.

@article{1774647,
   author = {Taborsky, Milos and Dušek, Ladislav and Kautzner, Josef and Vicha, Marek and Aiglova, Renata and Gloger, Vit and Fedorco, Marian and Duba, Jaroslav and Dusek, Lukas and Jarkovský, Jiří and Bezdekova, Monika and Skala, Tomas},
   article_location = {Oxford},
   article_number = {4},
   doi = {http://dx.doi.org/10.1093/europace/euaa261},
   keywords = {Atrial fibrillation; Stroke; Epidemiology; Prevalence; Prevention; Anticoagulation; European Union; Czech Republic},
   language = {eng},
   issn = {1099-5129},
   journal = {EP Europace},
   title = {SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation},
   url = {https://academic.oup.com/europace/article-abstract/23/4/539/6030920?redirectedFrom=fulltext},
   volume = {23},
   year = {2021}
}

TY  - JOUR
ID  - 1774647
AU  - Taborsky, Milos - Dušek, Ladislav - Kautzner, Josef - Vicha, Marek - Aiglova, Renata - Gloger, Vit - Fedorco, Marian - Duba, Jaroslav - Dusek, Lukas - Jarkovský, Jiří - Bezdekova, Monika - Skala, Tomas
PY  - 2021
TI  - SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation
JF  - EP Europace
VL  - 23
IS  - 4
SP  - 539-547
EP  - 539-547
PB  - Oxford University Press
SN  - 10995129
KW  - Atrial fibrillation
KW  - Stroke
KW  - Epidemiology
KW  - Prevalence
KW  - Prevention
KW  - Anticoagulation
KW  - European Union
KW  - Czech Republic
UR  - https://academic.oup.com/europace/article-abstract/23/4/539/6030920?redirectedFrom=fulltext
N2  - Aims The aim of this study is to analyse the prevalence, epidemiology, and anticoagulation prevention of stroke or transient ischaemic attack (TIA) in Czech patients with atrial fibrillation (AF). Methods and results Retrospective observational analysis of diagnoses, procedures, and treatment reported to the Czech National Registry of Reimbursed Healthcare Services between 2015 and 2018. Prevalence of AF in 2018 was 4.3% of Czech population and the prevalence of stroke/TIA in AF patients was 22.3% with annual incidence of 181.62 cases per 100 000 inhabitants. In 2018, CHA(2)DS(2)-ASc score >= 4 was present in 98% AF patients in secondary and 59% in primary prevention, respectively, while the anticoagulation treatment was used by 71-81% of them. Between 2015 and 2018, the percentage of AF patients treated with warfarin monotherapy in primary prevention decreased from 35% to 31%, with acetylsalicylic acid (ASA) monotherapy from 18% to 16% and non-vitamin K antagonist oral anticoagulants (NOACs) monotherapy increased from 7% to 11%. In secondary prevention, the percentage of warfarin monotherapy treatment decreased from 35% to 32%, with ASA monotherapy from 20% to 18% and with NOACs monotherapy increased from 9% to 15%. Conclusion This study followed all Czech patients with AF. The unadjusted prevalence and incidence of AF was higher compared with other countries and 2019 European Society of Cardiology Statistics. The study identified several gaps in standard of reimbursed care. 20-30% of AF patients with other risk factors were without any prevention medication and the share of ASA monotherapy in treated patients was 16-18%.
ER  -

TABORSKY, Milos, Ladislav DUŠEK, Josef KAUTZNER, Marek VICHA, Renata AIGLOVA, Vit GLOGER, Marian FEDORCO, Jaroslav DUBA, Lukas DUSEK, Jiří JARKOVSKÝ, Monika BEZDEKOVA and Tomas SKALA. SETAP: epidemiology and prevention of stroke and transient ischaemic attack in Czech patients with atrial fibrillation. \textit{EP Europace}. Oxford: Oxford University Press, 2021, vol.~23, No~4, p.~539-547. ISSN~1099-5129. Available from: https://dx.doi.org/10.1093/europace/euaa261.

Detailed Information on Publication Record